Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 15/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474653 | 0.86 | MPL (0.75) | MPLLTA4HHSD17B10KDM4EMEN1 | |
| SCHEMBL5330380 | 0.85 | MPL (0.74) | MPLLTA4HHSD17B10KDM4EMEN1 | |
| SCHEMBL30122919 | 0.85 | MPL (0.74) | MPLLTA4HHSD17B10KDM4EMEN1 | |
| SCHEMBL5591027 | 0.80 | MPL (0.67) | MPL | |
| SCHEMBL474677 | 0.80 | MPL (0.74) | MPLHSD17B10KDM4EMEN1MAPT | |
| SCHEMBL1803123 | 0.78 | MPL (0.64) | MPLLTA4HHSD17B10KDM4EMEN1 | |
| SCHEMBL4876821 | 0.78 | MPL (1.00) | MPLHSD17B10KDM4EMEN1MAPT | |
| SCHEMBL1801817 | 0.78 | MPL (0.63) | MPLHSD17B10KDM4EMEN1MAPT | |
| SCHEMBL23364670 | 0.75 | MPL (0.60) | MPLLTA4HHSD17B10KDM4EMEN1 | |
| SCHEMBL29932718 | 0.75 | MPL (0.60) | MPLLTA4HHSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007004038-A1 | AMINOTHIAZOLE DERIVATIVES AS AGONISTS OF THE THROMBOPOIETIN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-01-11 | — | — | WO | claimed |
| US-20210253871-A1 | CORROSION-RESISTANT CONDUCTIVE STRUCTURE AND CORROSION-RESISTANT COATING COMPOSITION | TPK UNIVERSAL SOLUTIONS LIMITED (HK) | 2021-08-19 | — | — | US | disclosed |
| CN-212848363-U | Corrosion resistant conductive structure | 宸盛光电有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-111192857-A | Corrosion-resistant conductive structure and corrosion-resistant coating composition | 宸盛光电有限公司 | 2020-05-22 | — | — | CN | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| CN-103755720-B | Thienopyrimidine derovatives as TRPA1 regulator | 格兰马克药品股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| EP-2708538-B1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-06-04 | — | — | US | disclosed |
| WO-2010109328-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| US-7169931-B2 | Cell differentiation, cell proliferation | SHIONOGI & CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-7169931-B2 | Cell differentiation, cell proliferation | SHIONOGI & CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-7169931-B2 | Cell differentiation, cell proliferation | SHIONOGI & CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| WO-2007004038-A1 | AMINOTHIAZOLE DERIVATIVES AS AGONISTS OF THE THROMBOPOIETIN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20040082626-A1 | Cyclic compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1361220-A1 | CYCLIC COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | MPL 2776/4885LTA4H 129/4885HSD17B10 2853/4885 |
| US-20040082626-A1 | Cyclic compounds exhibiting thrombopoietin receptor agonism | TEK, MPL, NPY1R | MPL 2/4885LTA4H 1119/4885HSD17B10 2592/4885 |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | MPL 1/4885LTA4H 1435/4885HSD17B10 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.